In light of the fact that rare exonic deletions implicate gephyrin in risk for autism, schizophrenia and seizures55, we propose that a better understanding of rMS-mediated changes in gephyrin-dependent inhibitory synaptic plasticity (under physiological and pathological conditions) may provide the perspective to transfer basic science knowledge into clinical practice and eventually devise new diagnostic and therapeutic strategies using non-invasive brain stimulation techniques. Here, GPHN is linked to autism.